Tag: financial results

Company will announce second quarter 2025 financial results and host a conference call on August 14, 2025

MONTRÉAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) today announced its financial results for the second quarter and six months ended June 30, 2025.

Shenzhen, China , Aug. 08, 2025 (GLOBE NEWSWIRE) -- On August 7, 2025, Beijing time, Lexin (NASDAQ: LX), China’s leading new-consumption digital technology service provider, today announced its unaudited financial results for the second quarter of 2025: revenue reached RMB 3.59 billion , up 15.6% quarter-over-quarter (QoQ); profit (Non-GAAP EBIT) was RMB 670 million , up 15.2% QoQ and 116.4% year-over-year (YoY). Q2 profit was the highest in 14 quarters, marking the fifth straight quarter of sequential growth, while multiple core business indicators continued to improve.

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the second quarter ended June 30, 2025 and declared a $1.00 per share dividend payable on October 10, 2025 to all common shareholders of record at close of business on September 19, 2025. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated.

VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, will release its financial results for the three and six months ended June 30, 2025 (“Q2 2025”) before market open on Monday, August 18, 2025.

Management to host conference call on Monday, August 11, 2025, at 4:30 PM ET

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.